Advertisement

Significance of Prognostic Factors During an Idarubicin-Containing Regimen in Adult AML

  • G. Lambertenghi Deliliers
  • C. Annaloro
  • E. Pozzoli
  • A. Oriani
  • R. Mozzana
  • E. E. Polli
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

The results of several clinical studies have clearly demonstrated that the anthracycline derivative idarubicin (IDR) exerts a potent activity on both refractory [1, 2] and previously untreated acute leukemia patients [3–6]. Furthermore, in randomized trials, IDR has been shown to be more active in inducing complete remission (CR) than the parent compound daunorubicin (DNR) [3–5]. More recently, it has been suggested that IDR improves the quality of the antineoplastic response, as testified by the high percentage of patients achieving CR after only one induction course; this increase in the speed of cytoreduction may also playa primary role in prolonging disease free survival [DFS]. As a further proof of its antileukemic activity, IDR seems to minimize the influence of several prognostic factors, including age WBC count and FAB type, on the achievement of CR [7].

Keywords

Complete Remission Acute Leukemia Acute Myelogenous Leukemia Cytosine Arabinoside Acute Myelogenous Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lambertenghi Deliliers G, Maiolo AT, Annaloro C, Crotelezzi A, Pogliani E, Ganzina F, Polli EE (1987) Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute nonlymphoblastic leukemia. Eur J Cancer Clin Oncol 23: 1041–1045CrossRefGoogle Scholar
  2. 2.
    Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin SJ, Hancock C, Williams L, Stevens YW, Clarkson BD, Young CW (1989) 4-Demethoxydaunorubicin (idarubicin) in combination with I-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Cancer Res 49: 477–481PubMedGoogle Scholar
  3. 3.
    Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, Clarkson BD (1989) Idarubicin in acute leukemia: results of the studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 16 (2): 30–34PubMedGoogle Scholar
  4. 4.
    Vogler WR, Velez-Garcia E, Omura G, Raney M (1989) A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Semin Oncol 16 (2): 21–24PubMedGoogle Scholar
  5. 5.
    Wiernik PH, Case DC, Periman PO, Arlin ZA, Weitberg AB, Ritch PC, Todd MB (1989) A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult non-lymphocytic leukemia. Semin Oncol 16 (2): 25–29PubMedGoogle Scholar
  6. 6.
    Lambertenghi Deliliers G, Annaloro C, Cortelezzi A, Cortellaro M, Della Volpe A, Maiolo AT, Mozzana R, Pogliani E, Pozzoli E, Polli EE (1989) Idarubicin plus cytarabine as first-line treatment of acute non lymphoblastic leukemia. Semin Oncol 16 (2): 16–20Google Scholar
  7. 7.
    Berman E, Heller G, Santorsa JA, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O’Reilly R, Jhanwar S, Young C, Clarkson B (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666–1674PubMedGoogle Scholar
  8. 8.
    Foon KA, Gale RP (1982) Controversies in the therapy of acute myelogenous leukemia. Am J Med 72: 963–979PubMedCrossRefGoogle Scholar
  9. 9.
    Champlin R, Gale RP (1987) Bone marrow transplantation for acute leukemia; recent advances and comparison with alternative therapies. Semin Hematol 24: 55–67PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • G. Lambertenghi Deliliers
    • 1
  • C. Annaloro
    • 1
  • E. Pozzoli
    • 1
  • A. Oriani
    • 1
  • R. Mozzana
    • 1
  • E. E. Polli
    • 1
  1. 1.Department of Hematology/OncologyHannover Medical SchoolHannoverGermany

Personalised recommendations